MA50455A - Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur - Google Patents

Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur

Info

Publication number
MA50455A
MA50455A MA050455A MA50455A MA50455A MA 50455 A MA50455 A MA 50455A MA 050455 A MA050455 A MA 050455A MA 50455 A MA50455 A MA 50455A MA 50455 A MA50455 A MA 50455A
Authority
MA
Morocco
Prior art keywords
pain
alcoxyamino
derivatives
associated conditions
pain associated
Prior art date
Application number
MA050455A
Other languages
English (en)
Inventor
Carmen Almansa-Rosales
Félix Cuevas-Cordobés
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MA50455A publication Critical patent/MA50455A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050455A 2017-10-27 2018-10-26 Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur MA50455A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382721 2017-10-27

Publications (1)

Publication Number Publication Date
MA50455A true MA50455A (fr) 2021-06-02

Family

ID=60262875

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050455A MA50455A (fr) 2017-10-27 2018-10-26 Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur

Country Status (20)

Country Link
US (1) US11401270B2 (fr)
EP (1) EP3700890B1 (fr)
JP (1) JP2021500416A (fr)
KR (1) KR20200097694A (fr)
CN (1) CN111566091A (fr)
AR (1) AR113799A1 (fr)
AU (1) AU2018356556A1 (fr)
BR (1) BR112020008371A2 (fr)
CA (1) CA3084425A1 (fr)
ES (1) ES2905582T3 (fr)
IL (1) IL274254A (fr)
MA (1) MA50455A (fr)
MX (1) MX2020003575A (fr)
PH (1) PH12020550594A1 (fr)
PT (1) PT3700890T (fr)
RU (1) RU2020114523A (fr)
SG (1) SG11202003599UA (fr)
TW (1) TW201925179A (fr)
WO (1) WO2019081691A1 (fr)
ZA (1) ZA202002526B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021553058A1 (en) 2019-06-06 2022-07-25 Hutchison Medipharma Ltd Tricyclic compounds and their use
SMT202500238T1 (it) * 2021-01-29 2025-07-22 3Z Ehf Composti per l’uso nel trattamento di disturbo da iperattività e deficit di attenzione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
CA2497979A1 (fr) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. Derives de promedicaments a base de 1, 3-diamino-2-hydroxypropane
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
US7569604B2 (en) * 2004-06-22 2009-08-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
EP1820799A1 (fr) * 2004-11-10 2007-08-22 Wakamoto Pharmaceutical Co., Ltd. Dérivé de 2,3,4,5-tétrahydro-1h-1,5-benzodiazépine et préparation thérapeutique
WO2008073929A1 (fr) * 2006-12-11 2008-06-19 Wyeth Modulateurs de canal ionique
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
MY196791A (en) * 2016-05-06 2023-05-03 Esteve Pharmaceuticals Sa New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
WO2019076904A1 (fr) * 2017-10-16 2019-04-25 Esteve Pharmaceuticals, S.A. Dérivés de propanamine destinés au traitement de la douleur et des états pathologiques associés à la douleur

Also Published As

Publication number Publication date
KR20200097694A (ko) 2020-08-19
CN111566091A (zh) 2020-08-21
US20200299297A1 (en) 2020-09-24
TW201925179A (zh) 2019-07-01
JP2021500416A (ja) 2021-01-07
CA3084425A1 (fr) 2019-05-02
IL274254A (en) 2020-06-30
SG11202003599UA (en) 2020-05-28
EP3700890B1 (fr) 2021-11-17
BR112020008371A2 (pt) 2020-11-03
AU2018356556A1 (en) 2020-05-07
MX2020003575A (es) 2020-07-22
PT3700890T (pt) 2022-02-02
EP3700890A1 (fr) 2020-09-02
WO2019081691A1 (fr) 2019-05-02
AR113799A1 (es) 2020-06-10
US11401270B2 (en) 2022-08-02
RU2020114523A (ru) 2021-12-01
ZA202002526B (en) 2021-06-30
ES2905582T3 (es) 2022-04-11
PH12020550594A1 (en) 2021-02-15

Similar Documents

Publication Publication Date Title
IL271046A (en) Compounds for treating huntington's disease
EP3645014A4 (fr) Système d'agents d'endormissement à action retard
EP3734660A4 (fr) Élément d'imagerie
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3415071A4 (fr) Système d'endoscope
EP3437540A4 (fr) Support d'endoscope
FR3056393B1 (fr) Orthese d'extension de machoires
EP3609864C0 (fr) Inhibiteurs de hdac6 et agents d'imagerie
MA49006A (fr) Inhibiteurs d'ip6k
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
IL268905B (en) Phage therapy
EP3618723A4 (fr) Cathéter d'imagerie
DK3463351T3 (da) Behandling til parkinsons sygdom
EP3592377A4 (fr) Formes posologiques de kallicréine tissulaire 1
EP3686204A4 (fr) Dérivés de thiénodiazépine et leur application
EP3624839A4 (fr) Schémas posologiques d'immunoconjugués anti-cd33
EP3578955A4 (fr) Système d'imagerie
EP3632453A4 (fr) Agent d'amélioration de la qualité musculaire
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
EP3429569A4 (fr) Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris
EP3444345A4 (fr) Dérivé d'arnmicro-143
EP3358825A4 (fr) Élément d'imagerie, et endoscope
MA50455A (fr) Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur
EP3319980A4 (fr) Formulations permettant d'améliorer l'efficacité des médicaments hydrophobes